We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Greg Winter.
- Abstract
An interview with Cambridge Antibody Technology cofounder Greg Winter is presented. When asked why it took so long for the pharmaceutical industry to recognize the value of monoclonal antibodies (mAbs), he mentions how the large pharmaceutical firms did not believe in mAbs. Winter adds that the rise of biosimilars is hard to predict because it depends on market pressures and the attitude of various regulatory bodies. He also discusses the future of mAb therapies and the threats faced by the life science innovation in Great Britain.
- Subjects
UNITED Kingdom; WINTER, Greg; PHARMACEUTICAL industry; MONOCLONAL antibodies
- Publication
Nature Biotechnology, 2011, Vol 29, Issue 3, p190
- ISSN
1087-0156
- Publication type
Interview
- DOI
10.1038/nbt.1815